Abbott directors approve AbbVie split

Abbott Laboratories said its board of directors has approved a plan to spin off its pharmaceutical business into a separate company named AbbVie Inc.

The North Chicago, Ill., company also on Wednesday said that a special dividend will complete the separation of the business. Abbott shareholders will receive one share of AbbVie common stock for every share of Abbott they hold.

It will be paid Jan. 1 to Abbott shareholders as of Dec. 12. AbbVie stock is expected to start trading Jan. 2 on the New York Stock Exchange under the ticker symbol "ABBV," while Abbott shares will keep the "ABT" symbol.

AbbVie will focus solely on branded drugs, including top-seller Humira, an anti-inflammatory. The split is meant to free Abbott from the risks and obligations of developing pharmaceutical drugs, leaving it with a more predictable business built around nutritional formula, generic drugs and heart stents.

Abbott shares added 33 cents to $64.90 in premarket trading Thursday.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer breaks down the theme of stealth technology stocks. Cramer says companies that are using proprietary technology to invent entirely new markets and then dominate those markets, fall under that category.

  • Mad Money host Jim Cramer knows it can be difficult to stick with a stock that is going lower but says if you've done the homework, and the story isn't wildly off the rails, then stay long.

  • Mad Money host Jim Cramer, outlines the most common emotionally driven investor mistakes and expresses why it is important to not let skepticism run away with you.